{
    "2020-08-21": [
        [
            {
                "time": "",
                "original_text": "药明巨诺IPO：2年半经营亏损4.75亿，2款主力抗癌产品专利购自大股东 亏损",
                "features": {
                    "keywords": [
                        "药明巨诺",
                        "IPO",
                        "亏损",
                        "抗癌产品",
                        "专利"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "药明康德(603259.SH)获核准非公开发行不超过1.05亿股新股",
                "features": {
                    "keywords": [
                        "药明康德",
                        "非公开发行",
                        "新股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "QFII持股曝光：举牌透景生命，青睐小盘绩优",
                "features": {
                    "keywords": [
                        "QFII",
                        "举牌",
                        "透景生命",
                        "小盘绩优"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物板块回撤-10%，哪些医药基金更抗跌？",
                "features": {
                    "keywords": [
                        "医药生物",
                        "回撤",
                        "基金",
                        "抗跌"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "相对陌生但又颇具前景的CRO行业",
                "features": {
                    "keywords": [
                        "CRO行业",
                        "前景"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "历史罕见！全球第一私行，也来举牌A股了",
                "features": {
                    "keywords": [
                        "全球第一私行",
                        "举牌",
                        "A股"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【东北医药崔洁铭/樊翔宇】药明康德（6031259）中报点评：二季度业绩恢复明显，CRO高景气持续",
                "features": {
                    "keywords": [
                        "药明康德",
                        "中报",
                        "业绩恢复",
                        "CRO",
                        "高景气"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}